Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exicure, Inc.

7.93
+0.21502.79%
Post-market: 8.000.0750+0.95%19:42 EDT
Volume:95.13K
Turnover:726.78K
Market Cap:50.07M
PE:-4.26
High:8.09
Open:7.71
Low:7.30
Close:7.71
Loading ...

Exicure, Inc. (Nasdaq: Xcur) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (Aml)

THOMSON REUTERS
·
12 Apr

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Business Wire
·
12 Apr

Exicure FY24 EPS $(4.75) Up From $(10.55) YoY; Revenue $500K

Benzinga
·
19 Mar

Exicure, Inc. Reports Full Year 2024 Financial Results

THOMSON REUTERS
·
19 Mar

Exicure Inc - Cash May Not Be Sufficient to Fund Operations; Doubts Ability to Continue as Going Concern

THOMSON REUTERS
·
19 Mar

Press Release: Exicure, Inc. Reports Full Year 2024 Financial Results

Dow Jones
·
19 Mar

Exicure Gets Patent in Australia for Potential Cancer Treatment Combination

MT Newswires Live
·
14 Mar

Exicure, Inc. Announces Issuance of New Patent in Australia

THOMSON REUTERS
·
14 Mar

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Business Wire
·
14 Mar

Top Premarket Gainers

MT Newswires Live
·
04 Mar

Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement

MT Newswires Live
·
23 Jan

BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.

Reuters
·
23 Jan

Exicure announces purchase agreement with GPCR Therapeutics

TIPRANKS
·
23 Jan

Exicure Inc: Acquired From Gpcr All of Issued and Outstanding Equity Securities of Gpcr Therapeutics USA Inc

THOMSON REUTERS
·
23 Jan

Exicure - Co, Gpcr Enter License and Collaboration Agreement to Further Develop, Commercialize Gpcr’s Techs Related to Certain Ip, Patents

THOMSON REUTERS
·
23 Jan

Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Dow Jones
·
23 Jan